Aerosolised antibiotics: A critical appraisal of their use

Expert Opinion on Drug Delivery

Volumn 3, Issue 1, 2006, Pages 71-86

  Hagerman, Jennifer K ^a   Hancock, Kim E ^a   Klepser, Michael E ^a  

^a FERRIS STATE UNIVERSITY   (United States)

Author keywords

Aerosolised; Antibiotics; Bronchiectasis; Cystic fibrosis; Nebuliser; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; COLISTIN; COTRIMOXAZOLE; FLUCONAZOLE; ITRACONAZOLE; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PLACEBO; POLYMYXIN B; TOBRAGOBENS; TOBRAMYCIN;

AEROSOL; BRONCHIECTASIS; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DEVICE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG SPUTUM LEVEL; DRUG USE; HUMAN; INFECTION; LARYNX DISORDER; LUNG MYCOSIS; MAINTENANCE THERAPY; MICROBIAL COLONIZATION; NAUSEA; NEBULIZER; PNEUMOCYSTIS PNEUMONIA; REVIEW; TASTE DISORDER; TINNITUS; VENTILATOR ASSOCIATED PNEUMONIA; VOICE CHANGE;

AEROSOLS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; LUNG DISEASES; LUNG TRANSPLANTATION; MYCOSES; NEBULIZERS AND VAPORIZERS;

EID: 30344479127     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.1.71     Document Type: Review

References (91)

1. NIKOLAIZIK WH, JENNI-GALOVIC V, SCHONI MH: Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Eur. J. Pediatr. (1996) 155(7):608-611.
2. COLE PJ: The role of nebulized antibiotics in treating serious respiratory infections. J. Chemother. (2001) 13(4):354-362.
3. ESCHENBACHER WL, BOUSHEY HA, SHEPPARD D: Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am. Rev. Respir. Dis. (1984) 129(2):211-215.
4. LOWRY RH, WOOD AM, HIGENBOTTAM TW: Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin. Sci. (1988) 74(4):373-376.
5. WEBER A, MORLIN G, COHEN M et al.: Effect of nebulizer type and antibiotic concentration on device performance. Pediatr. Pulmonol. (1997) 23(4):249-260.
6. ALOTHMAN CA, ALSANDI MM, HO BL et al.: Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest (2002) 122(3):930-934.
7. PROBER CG, VALSON PD, JONES J: Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics (2000) 106(6):E89.
8. RAMSEY BW, PEPE MS, QUAN JM et al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. (1999) 340(1):23-30.
9. BURNS JL, VAN DALFSEN JM, SHAWAR RM et al.: Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. (1999) 179(5):1190-1196.
10. HODSON ME, GALLAGHER CG, GOVAN JR: A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. (2002) 20(3):658-664.
11. BARKER AF, COUCH L, FIEL SB et al.: Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. (2000) 162(2 Pt 1):481-485.
12. COUCH LA: Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest (2001) 120(3 Suppl.): 114S-117S.
13. SCHEINBERG P, SHORE E: A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest (2005) 127(4):1420-1426.
14. HARDY JG, NEWMAN SP, KNOCH M: Lung deposition from four nebulizers. Respir. Med. (1993) 87(6):461-465.
15. MALLOL J, RATTRAY S, WALKER G, COOK D, ROBERTSON CF: Aerosol deposition in infants with cystic fibrosis. Pediatr. Pulmonol. (1996) 21(5):276-281.
16. ILOWITE JS, GORVOY JD, SMALDONE GC: Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis (1987) 136(6):1445-1449.
17. CLAY MM, CLARKE SW: Wastage of drug from nebulisers: a review. J. R. Soc. Med. (1987) 80(1):38-39.
18. LIPPMANN M, YEATES DB, ALBERT RE: Deposition, retention, and clearance of inhaled particles. Br. J. Ind. Med. (1980) 37(4):337-362.
19. MATTHEWS LW, DOERSHUK CF: Inhalation therapy and postural drainage for the treatment of cystic fibrosis. Bibl. Paediatr. (1967) 86:297-314.
20. BRAIN JD, VALBERG PA: Deposition of aerosol in the respiratory tract. Am. Rev. Respir. Dis. (1979) 120(6):1325-1373.
21. NEWMAN SP: Aerosol deposition considerations in inhalation therapy. Chest (1985) 88(2 Suppl.):152S-160S.
22. NEWMAN SP, PELLOW PG, CLAY MM, CLARKE SW: Evaluation of jet nebulisers for use with gentamicin solution. Thorax (1985) 40(9):671-676.
23. NERBRINK O, DAHLBACK M, HANSSON HC: Why do medical nebulizers differ in their output and particle size characteristics? J. Aerosol Med. (1994) 7(3):259-276.
24. O'CALLAGHAN C, BARRY PW: The science of nebulised drug delivery. Thorax (1997) 52(Suppl. 2):S31-S44.
25. WOLFF RK, NIVEN RW: Generation of aerosolized drugs. J. Aerosol Med. (1994) 7(1):89-106.
26. DENNIS JH: Drug nebuliser design and performance: breath enhanced jet versus constant output versus ultrasonic. J. Aerosol Med. (1995) 8(3):277-280.
27. EVERARD ML, CLARK AR, MILNER AD: Drug delivery from jet nebulisers. Arch. Dis. Child. (1992) 67(5):586-591.
28. COATES AL, MACNEISH CF, MEISNER D et al.: The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest (1997) 111(5):1206-1212.
29. LOFFERT DT, IKLE D, NELSON HS: A comparison of commercial jet nebulizers. Chest (1994) 106(6):1788-1792.
30. CHUA HL, COLLIS GG, NEWBURY AM et al.: The influence of age on aerosol deposition in children with cystic fibrosis. Eur. Respir. J. (1994) 7(12):2185-2191.
31. LEUNG K, LOUCA E, COATES AL: Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest (2004) 126(5):1619-1627.
32. COATES AL, HO SL: Drug administration by jet nebulization. Pediatr. Pulmonol. (1998) 26(6):412-423.
33. FAURISSON F, DESSANGES JF, GRIMFELD A et al.: Nebulizer performance: AFLM study. Association Francaise de Lutte contre la Mucoviscidose. Respiration (1995) 62(Suppl. 1):13-18.
34. NEWHOUSE MT, HIRST PH, DUDDU SP et al.: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest (2003) 124(1):360-366.
35. GELLER DE, ROSENFELD M, WALTZ DA, WILMOTT RW: Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest (2003) 123(1):28-36.
36. MARTONEN TB, KATZ IM: Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters. Pharm. Res. (1993) 10(6):871-878.
37. SANGWAN S, GURSES BK, SMALDONE GC: Facemasks and facial deposition of aerosols. Pediatr. Pulmonol. (2004) 37(5):447-452.
38. MUKHOPADHYAY S, STADDON GE, EASTMAN C et al.: The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir. Med. (1994) 88(3):203-211.
39. GELLER DE, PITLICK WH, NARDELLA PA, TRACEWELL WG, RAMSEY BW: Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest (2002) 122(1):219-226.
40. TOUW DJ, JACOBS FA, BRIMICOMBER W et al.: Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. (1997) 41(1):184-187.
41. COONEY GF, LUM BL, TOMASELLI M, FIEL SB: Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. (1994) 34(3):255-259.
42. VALCKE Y, PAUWELS R, VAN DER STRAETEN M: Pharmacokinetics of antibiotics in the lungs. Eur. Respir. J. (1990) 3(6):715-722.
43. MENDELMAN PM, SMITH AL, LEVY J et al.: Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. (1985) 132(4):761-765.
44. LEVY J, SMITH AL, KENNY MA, RAMSEY B, SCHOENKNECHT FD: Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J. Infect. Dis. (1983) 148(6):1069-1076.
45. PENNINGTON JE: Penetration of antibiotics into respiratory secretions. Rev. Infect. Dis. (1981) 3(1):67-73.
46. Cystic Fibrosis Foundation, Patient Registry 2003 Annual Report, Bethesda, Maryland, MD, USA (2003).
47. MOSS RB: Administration of aerosolized antibiotics in cystic fibrosis patients. Chest (2001) 120 (3 Suppl.): 107S-113S.
48. BARKER AF: Bronchiectasis. N. Engl. J. Med. (2002) 346(18):1383-1393.
49. ANGRILL J, AGUSTI C, DE CELIS R et al.: Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax (2002) 57(1):15-19.
50. NICOTRA MB, RIVERA M, DALE AM, SHEPHERD R, CARTER R: Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest (1995) 108(4):955-961.
51. WILSON CB, JONES PW, O'LEARY CJ et al.: Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. (1997) 10(8):1754-1760.
52. DROBNIC ME, SUNE P, MONTORO JB, FERRER A, ORRIOLS R: Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother. (2005) 39(1):39-44.
53. RAMSEY BW, DORKIN HL, EISENBERG JD et al.: Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. (1993) 328(24):1740-1746.
54. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. (2005) 171(4):388-416.
55. RELLO J, OLLENDORF DA, OSTER G et al.: Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest (2002) 122(6):2115-2121.
56. COOK DJ, WALTER SD, COOK RJ et al.: Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann. Intern. Med. (1998) 129(6):433-440.
57. CHASTRE J, FAGON JY: Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. (2002) 165(7):867-903.
58. KLASTERSKY J, HUYSMANS E, WEERTS D, HENSGENS C, DANEAU D: Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study. Chest (1974) 65(6):650-654.
59. KLICK JM, DU MOULIN GC, HEDLEY-WHYTE J et al.: Prevention of Gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. J. Clin. Invest. (1975) 55(3):514-519.
60. FEELEY TV, DU MOULIN GC, HEDLEY-WHYTE J et al.: Aerosol polymyxin and pneumonia in seriously ill patients. N. Engl. J. Med. (1975) 293(10):471-475.
61. WOOD GC, BOUCHER BA, CROCE MA et al.: Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Pharmacotherapy (2002) 22(8):972-982.
62. MEDURI GU, HEADLEY S, KOHLER G et al.: Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome overtime. Chest (1995) 107(4):1062-1073.
63. MEDURI GU, KANANGAT S, STEFAN J, TOLLEY E, SCHABERG D: Cytokines IL-1beta, IL-6, and TNF-alpha enhance in vitro growth of bacteria. Am. J. Respir. Crit. Care Med. (1999) 160(3):961-967.
64. RODRIGUEZ JL, MILLER CG, DEFORGE LE et al.: Local production of interleukin-8 is associated with nosocomial pneumonia. J. Trauma (1992) 33(1):74-81; discussion 81-72.
65. BONTEN MJ, FROON AH, GAILLARD CA et al.: The systemic inflammatory response in the development of ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. (1997) 156(4 Pt 1):1105-1113.
66. PALMER LB, SMALDONE GC, SIMON SR, O'RIORDAN TG, CUCCIA A: Aerosolized an ribiotics in mechanically ventilated patients: delivery and response. Crit. Care Med. (1998) 26(1):31-39.
67. SCHEFFER J, KONIG W: Cephalosporins and inflammatory host reactions. Respiration (1993) 60(Suppl. 1):25-31.
68. NICOD LP, PACHE JC, HOWARTH N: Fungal infections in transplant recipients. Eur. Respir. J. (2001) 17(1):133-140.
69. BEYER J, SCHWARTZ S, HEINEMANN V, SIEGERT W: Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrob. Agents Chemother. (1994) 38(5):911-917.
70. CAHILL BC, HIBBS JR, SAVIK K et al.: Aspergill us airway colonization and invasive disease after lung transplantation. Chest (1997) 112(5):1160-1164.
71. MEHRAD B, PACIOCCO G, MARTINEZ FJ et al.: Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest (2001) 119(1):169-175.
72. SINGH N: Invasive mycoses in organ transplant recipients: controversies in prophylaxis and management. J. Antimicrob. Chemother. (2000) 45(6):749-755.
73. REICHENSPURNER H, GAMBERG P, NITSCHKE M et al.: Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant. Proc. (1997) 29(1-2):627-628.
74. CALVO V, BORRO JM, MORALES P et al.: Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest (1999) 115(5):1301-1304.
75. SCHWARTZ S, BEHRE G, HEINEMANN V et al.: Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood (1999) 93(11):3654-3661.
76. DREW RH, DODDS ASHLEY E, BENJAMIN DK JR et al.: Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation (2004) 77(2):232-237.
77. BEYER J, BARZEN G, RISSE G et al.: Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. (1993) 37(6):1367-1369.
78. PALMER SM, DREW RH, WHITEHOUSE JD et al.: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation (2001) 72(3):545-548.
79. BEHRE GF, SCHWARTZ S, LENZ K et al.: Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann. Hematol. (1995) 71(6):287-291.
80. HERTENSTEIN B, KERN WV, SCHMEISER T et al.: Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann. Hematol. (1994) 68(1):21-26.
81. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin. Trials (2001) 2(6):493-554.
82. BOZZETTE SA, FINKELSTEIN DM, SPECTOR SA et al.: A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N. Engl. J. Med. (1995) 332(11):693-699.
83. SCHNEIDER MM, HOEPELMAN AI, EEFTINCK SCHATTENKERK JK et al.: A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N. Engl. J. Med. (1992) 327(26):1836-1841.
84. LEOUNG GS, FEIGAL DW, JR., MONTGOMERY AB et al.: Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N. Engl. J. Med. (1990) 323(12):769-775.
85. O'RIORDAN TG, SMALDONE GC: Exposure of health care workers to aerosolized pentamidine. Chest (1992) 101(6):1494-1499.
86. MONTGOMERY AB, CORKERY KJ, BRUNETTE ER et al.: Occupational exposure to aerosolized pentamidine. Chest (1990) 98(2):386-388.
87. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in healthcare facilities, 1994. MMWR (1994) 43(No. RR13):35-36.
88. VASSAL S, TAAMMA R, MARTY N et al.: Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am. J. Infect. Control (2000) 28(5):347-351.
89. ROSENFELD M, EMERSON J, ASTLEY S et al.: Home nebulizer use among patients with cystic fibrosis. J. Pediatr. (1998) 132(1):125-131.
90. JENSEN T, PEDERSEN SS, GARNE S et al.: Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. (1987) 19(6):831-838.
91. ORRIOLS R, ROIG J, FERRER J et al.: Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir. Med. (1999) 93(7):476-480.